Avalyn Pharma (NASDAQ:AVLN) Stock Crosses Above 50-Day Moving Average – What’s Next?

Avalyn Pharma Inc. (NASDAQ:AVLN) passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $29.11 and traded as high as $29.18. Avalyn Pharma shares last traded at $29.15, with a volume of 630,263 shares.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on AVLN shares. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a research note on Thursday, August 13th. They issued a “sell (d+)” rating on the stock. Raymond James Financial began coverage on Avalyn Pharma in a research note on Friday, October 2nd. They issued an “outperform” rating and a $60.00 target price on the stock. Wall Street Zen cut Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Finally, Morgan Stanley boosted their target price on Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.00.

Avalyn Pharma Price Performance

The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.29 billion and a P/E ratio of -1.28. The business’s 50-day moving average is $29.11.

Avalyn Pharma (NASDAQ:AVLN) last issued its earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.05. On average, analysts predict that Avalyn Pharma Inc. will post -3.86 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Avalyn Pharma during the 3rd quarter worth about $29,000. Manchester Capital Management LLC acquired a new stake in Avalyn Pharma in the third quarter valued at $36,000. Profund Advisors LLC bought a new stake in Avalyn Pharma in the 3rd quarter valued at about $668,000. Bank of New York Mellon Corp purchased a new position in shares of Avalyn Pharma in the 2nd quarter worth approximately $1,321,000. Finally, State Street Corp purchased a new position in shares of Avalyn Pharma during the 2nd quarter valued at $10,501,000.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc (NASDAQ: AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company’s research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.